Tag Archives: Obamacare
By Tom Norton | Published: December 9, 2014
At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” — read on.
By Jill Wechsler | Published: November 6, 2014
The 2014 mid-term elections handed over control of the Senate to Republicans and boosted the GOP majority in the House, a clear blow to Obama administration policies, including the president’s landmark health reform initiative. Voters were most dismayed about the economy and lack of jobs, but U.S. military snafus overseas and concerns about the Ebola […]
By Jill Wechsler | Published: November 3, 2014
A federal policy issued late last week appeared to deal a serious blow to continuing medical education (CME) programs supported by biopharma companies. But the specifics published by the Centers for Medicare and Medicaid Services (CMS) Oct. 31, 2014 actually continue to exempt independent CME funding from the Open Payments reporting requirements for transfers of […]
By Pharm Exec | Published: October 23, 2014
This month’s special issue of Pharm Exec Global Digest looks at Dealing with the “side effects” of Obamacare The “value” of Rxs under Obamacare The escalating cost of US oncology care And more… Click here to read the issue.
By Guest Blogger | Published: October 3, 2014
By Sydney Rubin. With more than 8 million Americans now signed up for health insurance through state health exchanges, The Affordable Care Act (ACA) has begun delivering benefits and new insurance protections to a large swath of Americans, many of whom had no health insurance before. People previously rejected by insurers due to pre-existing conditions […]